




ZEBRAHUB



BY ANOVA


AGENDA

- WHAT INSPIRED US?
- OUR SOLUTION
- KEY FEATURES
- TECHNOLOGY STACK
- SUMMARY



WHAT INSPIRED US?

Families and patients with rare diseases face barriers in:

- Tracking symptoms
 - Accurately recording health data
 - Receiving timely updates on clinical trials
 - Accessing jointed medical records
- 

ABOUT ZEBRA HUB

We built a patient-friendly platform that makes it easy for individuals with rare diseases to track their symptoms, record health data, and stay updated on their clinical trials—all in one place.



Daily Check-in

Clinical Trials

Appointments

Analytics

Updates

Clinical Trial: NCT05794139

Location: San Diego, California, United States, 92120

3 months

1 year

2 years

Phase 1
General Study

Phase 2
Safety

Phase 3
New Dose

Contact Information

Company Name: NMD Pharma A/S

Investigator Name: Anna Hathway

Investigator Contact: +1 (567)576-8790

Physician Name: Michael Chris

Medication

DrugName : NMD670

Phase 1: NMD670
Vutrisiran (ALN-TTRsc02)
ganaxolone

Phase 2: NMD671
ARO-APOC3 (Plozasiran)

KEY FEATURES

Last Login: 12 Feb 2025 10:00 AMLogout

Daily Check-In

Mood Scale: 3

Please rate on a scale from 1-5, 1 being the worst.

☐ Sleep Disturbance


☐ Appetite/Cravings

☐ Abnormal Energy Levels

Adverse Reactions:

Submit

- DAILY CHECK-INS
- PROGRESS VIEW
- CLINICAL TRIALS
 - PERSONALIZED MESSAGES FROM INVESTIGATORS
 - MEDICATIONS DELIVERY STATUS
- APPOINTMENT REMINDER



METHODS/CHALLENGES

Tech Stack

- Supabase Postgres
- Django
- React
- TailwindCSS
- Material UI
- ChartJS
- Figma

Challenges

- Limited/no experience with using Django
- Addressing all aspects of the problem statement in 30 hours